STRIVE STUDY OVERVIEW
The earlier that cancer can be found, the better the chance it can be successfully treated.
The STRIVE Study is supporting the development of a new tool for early cancer detection that finds small pieces of genomic material coming from cancer allowing for early cancer detection.
The goal of the STRIVE Study is to understand if the blood test under development is able to detect cancer early. The study enrolled women who donated blood at the time of their screening mammogram, and agreed to have their medical records followed for up to 5 years from the date of enrollment to monitor their health status.
Learn more about early detection and the role of this blood test.
Study follow-up involves collecting information from participants to confirm their health status. STRIVE research teams at participating locations will be reaching out to participants occasionally to collect follow-up information. Each follow-up contact will only take about 5 minutes of your time. Study researchers will also be actively monitoring electronic health records for up to 5 years from the date of enrollment to capture clinical outcome data, including cancer diagnoses.
You will not receive any personal test results because this is a research study and the test is still under development.